Metapramine

Metapramine
Systematic (IUPAC) name
(±)-10,11-dihydro-N,5-dimethyl-5H-dibenz[b,f]azepin-10-amine
Clinical data
Routes of
administration		 Oral
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Biological half-life 7-8 hours
Identifiers
CAS Number 21730-16-5
ATC code none
PubChem CID 65700
ChemSpider 59127
UNII 303954M7YF YesY
Chemical data
Formula C16H18N2
Molar mass 238.33 g/mol
Chirality Racemic mixture

Metapramine (trade names Prodastene, Timaxel) is a tricyclic antidepressant (TCA) developed by Rhone Poulenc[1] that was introduced for the treatment of depression in France in 1984.[2][3] In addition to its efficacy against affective disorders, it also has analgesic properties,[4][5] and may be useful in the treatment of pain.

Metapramine has desipramine-like effects, acting as a norepinephrine reuptake inhibitor without affecting the reuptake of serotonin or dopamine.[6][7][8] It has also been shown to act as a low-affinity NMDA receptor antagonist.[9] Metapramine's direct effects on serotonin, histamine, and muscarinic acetylcholine receptors have not been assayed, but uniquely among most TCAs, it has anecdotally been reported to lack anticholinergic effects.[8][10]

References

  1. ↑ US Patent 3622565 - DIBENZAZEPINE DERIVATIVES AND THEIR PREPARATION
  2. ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. p. 13. ISBN 0-412-54090-8.
  3. ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 248. ISBN 3-527-31058-4.
  4. ↑ Michael-Titus A, Costentin J (December 1987). "Analgesic effects of metapramine and evidence against the involvement of endogenous enkephalins in the analgesia induced by tricyclic antidepressants". Pain 31 (3): 391–400. doi:10.1016/0304-3959(87)90167-9. PMID 2827090.
  5. ↑ Fialip J, Marty H, Aumaitre O, et al. (1992). "Antinociceptive activity of metapramine in mice. Relationship with its pharmacokinetic properties". Life Sciences 50 (3): 161–8. doi:10.1016/0024-3205(92)90268-T. PMID 1731171.
  6. ↑ Dagonneau H, Fonlupt P, Pacheco H (1986). "[Effects, in rats, of metapramine and carpipramine on the uptake of catecholamines and serotonin; relationship with 3H-imipramine binding]". Comptes rendus des séances de la Société de biologie et de ses filiales (in French) 180 (1): 43–8. PMID 3017518.
  7. ↑ Warter JM, Tranchant C, Marescaux C, Depaulis A, Lannes B, Vergnes M (1990). "Immediate effects of 14 non MAOI antidepressants in rats with spontaneous petit mal-like seizures". Progress in Neuro-psychopharmacology & Biological Psychiatry 14 (2): 261–70. doi:10.1016/0278-5846(90)90106-q. PMID 2106711.
  8. 1 2 Bonierbale M, Dufour H, Scotto JC, Sutter JM (1976). "[Metapramine: antidepressant and psycho-stimulant]". L'Encéphale (in French) 2 (3): 219–23. PMID 1033059.
  9. ↑ Boireau A, Bordier F, Durand G, Doble A (1996). "The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors". Neuropharmacology 35 (12): 1703–7. doi:10.1016/S0028-3908(96)00122-0. PMID 9076749.
  10. ↑ Dufour P, Billa JP, Fabre J, Roquebert J (1989). "[Evaluation of the central anticholinergic activity of antidepressants. Comparison of two experimental methods]". Annales Pharmaceutiques Françaises (in French) 47 (3): 135–41. PMID 2634929.


This article is issued from Wikipedia - version of the Monday, March 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.